Harnessing the immune system for cancer therapy.
Smith EL et al. Curr Opin Oncol. 2014 Sep 23. [Epub ahead of print].
CCN1: a sticky issue in myeloma.
Roodman GD. Blood. 2014 Sep 25;124(13):2006-8. doi: 10.1182/blood-2014-08-592303.
Appraising Myc involvement in high risk myeloma.
Kastritis E et al. Leuk Lymphoma. 2014 Sep 26:1-5. [Epub ahead of print].
Longitudinal Analysis of Patient-Reported Symptoms Post-AuSCT and their Relationship to Inflammation in Patients with Multiple Myeloma.
Wang XS et al. Leuk Lymphoma. 2014 Sep 24:1-18. [Epub ahead of print].
Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy.
Bryan LJ et al. Blood Rev. 2014 Sep 16. pii: S0268-960X(14)00073-3. doi: 10.1016/j.blre.2014.09.004. [Epub ahead of print].
Therapeutic advancements in multiple myeloma.
Gozzetti A et al. Front Oncol. 2014 Sep 4;4:241. doi: 10.3389/fonc.2014.00241. eCollection 2014.
Symptoms of Anxiety and Depression Are Associated With Satisfaction With Information Provision and Internet Use Among 3080 Cancer Survivors: Results of the PROFILES Registry.
Beekers N et al. Cancer Nurs. 2014 Sep 14. [Epub ahead of print].
Two cases of nonsecretory multiple myeloma presenting as primary plasma cell leukemia.
Takahashi T et al. Intern Med. 2014;53(18):2121-5. Epub 2014 Sep 15.
TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA OVER 65 YEARS: MORE TOLERABİLİTY OR BETTER RESPONSE?
Tarkun P et al. Eur J Haematol. 2014 Sep 12. doi: 10.1111/ejh.12448. [Epub ahead of print].
Autologous hematopoietic cell transplantation: An update for clinicians.
Hamadani M. Ann Med. 2014 Sep 11:1-14. [Epub ahead of print].
Advances in the management of asymptomatic myeloma.
Mateos MV. Curr Opin Oncol. 2014 Sep 10. [Epub ahead of print].
Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups.
Ailawadhi S et al. Blood Cancer J. 2014 Sep 5;4:e243. doi: 10.1038/bcj.2014.63.
Current treatment for multiple myeloma.
Avigan D et al. N Engl J Med. 2014 Sep 4;371(10):961-2. doi: 10.1056/NEJMe1407442.